| Complicated urinary tract infection
Fetroja vs Vabomere
Side-by-side clinical, coverage, and cost comparison for complicated urinary tract infection.Deep comparison between: Fetroja vs Vabomere with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVabomere has a higher rate of injection site reactions vs Fetroja based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vabomere but not Fetroja, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fetroja
Vabomere
At A Glance
IV infusion
Every 8 hours
Cephalosporin antibacterial
IV infusion
Every 8 hours
Carbapenem + beta-lactamase inhibitor
Indications
- Complicated urinary tract infection
- Pyelonephritis
- Hospital acquired pneumonia
- Pneumonia, Ventilator-Associated
- Complicated urinary tract infection
- Pyelonephritis
Dosing
Complicated urinary tract infection, Pyelonephritis 2 grams IV infusion over 3 hours every 8 hours in adults with CLcr 60 to 119 mL/min; dose adjusted for CLcr <60 or >=120 mL/min; duration 7 to 14 days.
Hospital acquired pneumonia, Pneumonia, Ventilator-Associated 2 grams IV infusion over 3 hours every 8 hours in adults with CLcr 60 to 119 mL/min; dose adjusted for CLcr <60 or >=120 mL/min; duration 7 to 14 days.
Complicated urinary tract infection, Pyelonephritis 4 grams (meropenem 2 grams and vaborbactam 2 grams) IV infusion over 3 hours every 8 hours for up to 14 days in patients with eGFR >=50 mL/min/1.73m2; dose adjustment required for eGFR <50 mL/min/1.73m2 (2 grams every 8 hours for eGFR 30-49, 2 grams every 12 hours for eGFR 15-29, 1 gram every 12 hours for eGFR <15).
Contraindications
- Known history of severe hypersensitivity to cefiderocol, other beta-lactam antibacterial drugs, or any other component of FETROJA
- Known hypersensitivity to any component of VABOMERE (meropenem and vaborbactam) or to other drugs in the same class
- Demonstrated anaphylactic reactions to beta-lactam antibacterial drugs
Adverse Reactions
Most common (>=2%) Diarrhea, elevations in liver tests, hypokalemia, infusion site reactions, constipation, rash, candidiasis, headache, nausea, vomiting, hypomagnesemia, atrial fibrillation
Serious Increase in all-cause mortality in carbapenem-resistant gram-negative bacterial infections, hypersensitivity reactions, Clostridioides difficile-associated diarrhea, seizures and other central nervous system adverse reactions
Postmarketing Neutropenia, chromaturia
Most common (>=3%) Headache, phlebitis/infusion site reactions, diarrhea
Serious Hypersensitivity reactions, seizures, rhabdomyolysis, Clostridioides difficile-associated diarrhea, breakthrough seizures (valproic acid interaction), thrombocytopenia, neuromotor impairment
Postmarketing Rhabdomyolysis, drug-induced liver injury (DILI) including hepatitis and liver failure
Pharmacology
Cefiderocol is a cephalosporin antibacterial that functions as a siderophore, using the bacterial iron uptake mechanism to traverse the outer cell membrane and exert bactericidal activity by inhibiting cell wall biosynthesis through binding to penicillin-binding proteins (PBPs).
Meropenem is a penem antibacterial that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins in gram-positive and gram-negative bacteria; vaborbactam is a cyclic boronic acid, non-suicidal beta-lactamase inhibitor that protects meropenem from degradation by serine beta-lactamases, including Klebsiella pneumoniae carbapenemase (KPC), without intrinsic antibacterial activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fetroja
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Vabomere
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Fetroja
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vabomere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Fetroja
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Vabomere
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Fetroja.
No savings programs available for Vabomere.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FetrojaView full Fetroja profile
VabomereView full Vabomere profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.